UBS analyst Trung Huynh sees positive trial results supporti...

UBS analyst Trung Huynh sees positive trial results supporting continued uptake of GLP-1s. UBS's Eliana Merle defends Madrigal, highlighting Rezdiffra's advantages in the NASH market, with a Buy rating and $411 price target.